Stratasys (SSYS) announced that its TrueDent resins have received CE marking as a Class IIa medical device, making them Europe’s first high-esthetic, monolithic 3D-printed denture solution to achieve certification in the more than $2B market. The company said, “This milestone enables broader regulated clinical use and expands patient access to polychromatic, monolithic 3D-printed dentures, removable partial dentures, and crowns and bridges. The expanded indication now includes intraoral removables for long-term use of more than 30 days as well as crowns and bridges.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SSYS:
- Stratasys: Cost Discipline and Mixed Valuation Support Neutral Rating Amid Muted Growth Outlook
- Stratasys Earnings Call Balances Growth Plans and Headwinds
- Stratasys price target lowered to $12 from $14 at Craig-Hallum
- Stratasys Posts 2025 Loss but Improves Cash Flow and Margins, Issues 2026 Outlook
- Stratasys reports Q4 adjusted EPS 7c, consensus 6c
